Osteoarthritis Research Unit, University of Montreal Hospital Research Centre, Notre-Dame Hospital, Montreal, Quebec H2L 4M1, Canada.
J Rheumatol. 2010 Mar;37(3):656-64. doi: 10.3899/jrheum.090696. Epub 2010 Jan 28.
OBJECTIVE: During osteoarthritis (OA), the altered metabolism of cartilage involves proinflammatory factors and matrix metalloprotease (MMP) activity. Studies showed that chondroitin sulfate (CS) may exert a positive effect on the cartilage. Because of differences in CS in terms of purity and the production/purification process, we compared the effects of 3 different types of CS on human OA cartilage. METHODS: Three types of CS were tested: CS1 (porcine, purity 90.4%), CS2 (bovine, purity 96.2%), and CS3 (bovine, purity 99.9%). Treatment with CS at 200 and 1000 microg/ml was performed on human OA cartilage explants in the presence/absence of interleukin 1ss (IL-1ss), and the protein modulations of factors including prostaglandin E(2) (PGE(2)), IL-6, and MMP-1 measured by ELISA. The CS effect on the expression of collagen type II was also investigated on OA chondrocytes using quantitative polymerase chain reaction. RESULTS: In the presence of IL-1ss, CS2 at 1000 microg/ml significantly inhibited IL-6 and PGE(2) production, and CS3 at 200 microg/ml markedly reduced the level of IL-6. CS1 was much less efficient at reducing the catabolic markers and in the absence of IL-1ss, it significantly increased IL-6 and MMP-1. IL-1ss significantly inhibited the gene expression level of collagen type II; only CS3 was able to limit this inhibition. CS1, in the presence or absence of IL-1ss, further markedly decreased collagen type II expression. CONCLUSION: Our data indicate that among the 3 tested CS, CS1 increased production of some catabolic pathways and inhibited the gene expression level of collagen type II. Our study provides new information in the context of prescribing CS for alleviating OA symptoms, as the purity and/or production/purification of the CS compound could orient the current OA disease process toward increased catabolic pathways.
目的:在骨关节炎(OA)中,软骨代谢的改变涉及促炎因子和基质金属蛋白酶(MMP)活性。研究表明,硫酸软骨素(CS)可能对软骨产生积极影响。由于 CS 在纯度和生产/纯化过程方面存在差异,我们比较了 3 种不同类型的 CS 对人 OA 软骨的影响。
方法:测试了 3 种 CS:CS1(猪,纯度 90.4%)、CS2(牛,纯度 96.2%)和 CS3(牛,纯度 99.9%)。在存在/不存在白细胞介素 1ss(IL-1ss)的情况下,将 CS 以 200 和 1000μg/ml 的浓度处理人 OA 软骨外植体,并通过 ELISA 测量包括前列腺素 E(2)(PGE(2))、IL-6 和 MMP-1 在内的因子的蛋白调节。还使用定量聚合酶链反应研究了 CS 对 OA 软骨细胞中 II 型胶原表达的影响。
结果:在存在 IL-1ss 的情况下,CS2 以 1000μg/ml 显著抑制 IL-6 和 PGE(2)的产生,CS3 以 200μg/ml 显著降低 IL-6 水平。CS1 降低分解代谢标志物的效率要低得多,并且在没有 IL-1ss 的情况下,它显著增加了 IL-6 和 MMP-1。IL-1ss 显著抑制 II 型胶原的基因表达水平;只有 CS3 能够限制这种抑制。CS1 在存在或不存在 IL-1ss 的情况下,进一步显著降低了 II 型胶原的表达。
结论:我们的数据表明,在所测试的 3 种 CS 中,CS1 增加了一些分解代谢途径的产生,并抑制了 II 型胶原的基因表达水平。我们的研究在为缓解 OA 症状开 CS 处方的背景下提供了新的信息,因为 CS 化合物的纯度和/或生产/纯化过程可能会使当前的 OA 疾病进程向增加的分解代谢途径倾斜。
Arthritis Rheum. 2006-7
Tissue Eng Part A. 2025-1
Hua Xi Kou Qiang Yi Xue Za Zhi. 2023-8-1
Aging Clin Exp Res. 2019-6-26
Glycoconj J. 2016-10